Electroosmotic Pump Technology 2026 — PatSnap Eureka
Electroosmotic Pump Technology: Patent Landscape & Innovation Signals
Electroosmotic pumps — solid-state microfluidic devices with no moving parts — are reshaping precision drug delivery, genomics instrumentation, electronics cooling, and water purification. This landscape synthesises patent and literature signals across core mechanisms, application domains, and key assignees to map where the field stands in 2026.
How Electroosmotic Pumps Work
Electroosmotic pumps exploit the electroosmotic effect: when an electric potential is applied across a porous medium or capillary containing an electrolyte, the mobile ions in the diffuse layer of the electric double layer migrate toward the counter-electrode, dragging bulk fluid along. This produces net fluid flow proportional to the applied voltage and the zeta potential of the pore surfaces — with no moving mechanical parts.
The technology has matured from academic curiosity into a commercially relevant platform. Core technical sub-domains include porous membrane architectures (silica frits, ceramic membranes, nanoporous anodized aluminum oxide, and molecularly thin silicon membranes), electrode materials and electrochemistry, gas management, multi-membrane stacking, and zeta-potential modulation via atomic layer deposition or an independent third electrode.
Gas management remains a persistent technical challenge, addressed through bubble separation chambers, gas-permeable vents, and catalytic recombination. Players with proprietary non-precious-metal, non-gassing electrode chemistries hold defensible IP moats in drug delivery and implantable device markets. The WHO identifies implantable drug delivery as a priority area for chronic disease management, underscoring the clinical relevance of gas-free EO pump operation.
The PatSnap IP analytics platform was used to retrieve and analyse the patent and literature records underlying this landscape report.
Assignee Filing Counts & Jurisdictional Distribution
Data derived from targeted patent and literature searches via PatSnap Eureka. Represents a snapshot of innovation signals within this dataset only.
Top Assignees by Filing Count in Dataset
Stanford leads with 7 records; CAREMEDI and Illumina each hold 4 active/recent records in the dataset.
Patent Filings by Jurisdiction
US dominates with ~18 records; EP second with ~8; CN holds 5; emerging jurisdictions (AU, CA, NZ, IL) show growing activity.
Four Architectural Approaches Dominate the EO Pump Patent Landscape
From porous ceramic membranes to multi-layer stacked assemblies, each cluster addresses distinct performance trade-offs in pressure, flow rate, gas management, and manufacturability.
Porous Ceramic & Glass Membrane EO Pumps
The most prevalent architecture in the dataset. A ceramic or packed-silica-sphere membrane is sandwiched between two electrodes. DC voltage drives electroosmotic flow through the membrane's charged pores. Key performance levers are pore size, surface chemistry (zeta potential), and electrode material. University of Texas System patents demonstrate porous silver/silver oxide and cerium oxide-coated porous carbon electrodes enabling non-gassing DC operation at 0.1–3 V for drug delivery applications.
≤3V · Non-gassing DC operationThin Membrane & Nanomembrane EO Pumps
High-performance pumps exploiting molecularly thin or nanoporous membranes (pnc-Si, AAO) to minimize electrical resistance and maximize flow rate per unit voltage. University of Rochester's NIH-funded research demonstrated pnc-Si membranes achieving flow rates 20× higher than conventional low-voltage EOPs due to minimal electrical resistance and high electric fields across molecularly thin membranes. Old Dominion University's ALD-deposited thin-layer coatings enable active zeta-potential modulation via an embedded third electrode — a notable capability for dynamic flow control.
20× flow rate vs. conventional low-V EOPsConductive Polymer Electrode EO Pumps
A growing cluster using PEDOT:PSS, PEDOT:PSS composites, or porous carbon with conductive polymers to eliminate gas evolution through faradaic charge storage rather than water electrolysis. Sogang University Research Foundation's 2016 EP patent uses conductive polymer electrodes with anionic polymer inclusions where cation migration maintains charge balance without gassing. EOFlow Co., Ltd.'s 2023 US filings introduce dual-layer electrode architectures combining precious metal with conductive polymer for wearable insulin pump applications. This cluster is directly relevant to life sciences and biotech R&D teams.
Gas-free via faradaic charge storageMulti-Membrane Stacked & Self-Contained Architectures
Systems combining alternating positive and negative electroosmotic membranes, enabling higher pressure generation from low voltages and valve actuation without external power sources. General Electric's 2014 EP patent describes alternating positive/negative membranes with cathodes/anodes disposed between them, prechargeable for passive operation and capable of ≥0.75 PSI. EOFlow's 2023 three-electrode stacked architecture with alternating zeta-potential membranes enables enhanced pressure at low voltages for wearable applications. CAREMEDI's impermeable plate-substrate (titanium) electrode broadens electrode material scalability for commercial manufacturing — with active/pending status across EP, NZ, AU, and CA.
≥0.75 PSI · Passive pre-charged operationSix Application Domains Driving EO Pump Commercialisation
Drug delivery and genomics instrumentation dominate the dataset; water purification represents the highest-growth emerging vector.
Drug Delivery & Medical Devices
The single most densely cited application domain. EO pumps serve as precision, pulseless fluid delivery engines in implantable drug delivery systems and wearable infusion devices. Gas-free operation is critical. University of Texas System patents describe complete pump systems with cannula, reservoir, and controller for subcutaneous drug delivery. CAREMEDI's 2023–2025 filings across four jurisdictions explicitly target fluid pumping systems including medical contexts. PatSnap's life sciences solutions help R&D teams track this domain.
Genomics & Life Science Instrumentation
Illumina, Inc. is the dominant player, integrating EO pumps directly into flow cells used in next-generation DNA sequencing instruments. Their 2018 EP patent embeds the EO pump in the flow cell body itself, enabling miniaturized sequencing cartridges — a vertical integration strategy that creates razor-and-blade business model alignment and reduces IP vulnerability to third-party pump substitution. Illumina holds 4 records in the dataset spanning CN, CA, and EP jurisdictions. The NIH has funded related nanomembrane EO pump research (University of Rochester, 2016).
Electronics Thermal Management
Stanford University pioneered the use of EO pumps for chip-level cooling, exploiting their silent, vibration-free, scalable operation. Their 2004 US patent describes a high-pressure EO pump for closed-loop microelectronic cooling without moving parts. Intel Corporation filed on integration of EO pumps and microchannels into processor cooling layers (2009, HK/EP). As chip power densities continue rising, this application domain may see renewed commercial interest. IEEE has published extensively on microfluidic thermal management for electronics.
Fuel Cell Water Management
EO pumps integrated into fuel cells manage product water at the cathode, improving power density and enabling passive air-breathing designs. Stanford's 2006 US and 2007 EP patents describe an EO pump layer that removes water from the cathode, scalable from centimetre to micron fuel cells. These patents represent early-phase foundational work; several Stanford cooling and fuel cell patents have lapsed or are inactive in the dataset, potentially creating freedom-to-operate windows for new entrants — though comprehensive FTO analysis would require broader search coverage via PatSnap analytics.
Three Directional Shifts Reshaping the EO Pump Field
1. Reverse Electro-Osmotic Filtration for Water Purification and Implantable Organs. The Ecole Normale Superieure and Université Paris Cité filings (2021–2025) represent a new application paradigm: using EO principles in reverse to drive water filtration, desalination, and even implantable artificial kidney applications. The 2025 filing specifically uses alternating electric fields and asymmetric nanofluidic membranes to address polarization degradation in prior systems — a notable technical advance. The field is patent-sparse relative to drug delivery, creating early-mover opportunity for commercial entrants. The WHO estimates over 850 million people live with kidney disease globally, underscoring the clinical urgency.
2. Impermeable Substrate Electrode Platforms (Korea). CAREMEDI CO., LTD.'s 2023–2025 filings across EP, NZ, AU, and CA jurisdictions introduce a structural departure from conventional porous electrode substrates: impermeable plate substrates (e.g., titanium) with surface-coated electrode materials and defined fluid pathways. This approach dramatically broadens the palette of usable electrode materials, reduces fabrication constraints, and enables more scalable manufacturing. The simultaneous active/pending status across four jurisdictions signals active commercial prosecution. R&D teams and IP strategists should monitor these families via PatSnap IP analytics.
3. Multi-Electrode Stacked Membrane Assemblies for Wearable Drug Delivery. EOFlow Co., Ltd.'s 2023 filings on multi-electrode membrane assemblies introduce three-electrode stacked architectures with alternating zeta-potential membranes, enabling enhanced pressure at low voltages for wearable insulin pump and similar applications — consistent with EOFlow's commercial positioning in patch-type insulin delivery. This architecture builds on the General Electric multi-membrane framework while adding the conductive polymer electrode chemistry advances from Cluster 3. PatSnap customers in MedTech use Eureka to track exactly these prosecution signals.
Application Domain Activity Across Innovation Phases
Mapping which application domains emerged in each phase reveals how EO pump technology has diversified from electronics cooling into drug delivery, genomics, and now water purification.
Application Domain Emergence by Phase
Electronics cooling and fuel cells dominated early filings; drug delivery intensified from 2007; water purification appears only in 2021–2025 filings.
EO Pump Operating Principle: 5-Step Flow
From applied voltage to net fluid flow — the electroosmotic mechanism without moving parts.
Key Assignees, Filing Counts & Jurisdictional Focus
Innovation in this dataset is moderately concentrated, with academic institutions accounting for the majority of filings and commercial entities holding focused sub-domain positions.
Monitor CAREMEDI's multi-jurisdiction prosecution in real time
Track active and pending EO pump families across EP, NZ, AU, and CA with PatSnap Eureka alerts
Electroosmotic Pump Technology — key questions answered
Electroosmotic pumps are solid-state microfluidic devices that drive fluid through porous or channeled media by applying an electric field across a charged surface, generating flow via interaction with the electrical double layer — all without moving mechanical parts.
The technology has matured from academic curiosity into a commercially relevant platform enabling precision drug delivery, genomics instrumentation, electronics cooling, and emerging water purification applications.
Gas management is a persistent technical challenge, addressed through bubble separation chambers, gas-permeable vents, and catalytic recombination. For drug delivery and implantable devices, gas-free operation is critical and drives demand for non-gassing electrode chemistries.
Among the retrieved results, the Board of Trustees of the Leland Stanford Junior University leads with 7 records, followed by the Board of Regents of the University of Texas System with 5 records, CAREMEDI CO., LTD. with 4 records, and Illumina, Inc. with 4 records.
Based on the most recent filings (2022–2026), three directional shifts are identifiable: reverse electro-osmotic filtration for water purification and implantable organs, impermeable substrate electrode platforms from Korean filers (CAREMEDI), and multi-electrode stacked membrane assemblies for wearable drug delivery.
pnc-Si membranes exhibit flow rates 20× to several orders of magnitude higher than other low-voltage EOPs due to minimal electrical resistance and high electric fields across molecularly thin membranes.
Still have questions about electroosmotic pump patents? Let PatSnap Eureka answer them for you.
Ask Eureka AI About EO PumpsMap Every EO Pump Patent Before Your Competitors Do
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D and monitor emerging IP threats in microfluidics, drug delivery, and materials science.
References
- Electro-osmotic pump, method of manufacturing electrode, fluid pumping system using the same, and operation method thereof — CAREMEDI CO., LTD., 2025, EP
- Electro-osmotic pump, method of manufacturing electrode, fluid pumping system using the same, and operation method thereof — CAREMEDI CO., LTD., 2025, NZ
- Electro-osmotic pump, method of manufacturing electrode, fluid pumping system using the same, and operation method thereof — CAREMEDI CO., LTD., 2024, AU
- Electro-osmotic pump, method of manufacturing electrode, fluid pumping system using the same, and operation method thereof — CAREMEDI CO., LTD., 2023, CA
- Electroosmotic pump, method for manufacturing same, and fluid pumping system comprising same — EOFlow Co., Ltd., 2023, US
- Membrane-electrode assembly for electroosmotic pump, electroosmotic pump including same, and fluid pumping system — EOFlow Co., Ltd., 2023, US
- Reverse electro-osmotic filtration exploiting nanofluidic transport through asymmetric membrane — Ecole Normale Superieure, 2025, IL
- Reverse electro-osmotic filtration system and uses thereof — Ecole Normale Superieure, 2021, CA
- Reverse electro-osmotic filtration system and uses thereof — Université Paris Cité, 2024, IN
- Electroosmotic pump with improved gas management — Illumina, Inc., 2015, CA
- Flow cells and manifolds having an electroosmotic pump — Illumina, Inc., 2018, EP
- 具有改进的气体管理的电渗泵 (Electroosmotic pump with improved gas management) — Illumina, Inc., 2012, CN
- High-performance, low-voltage electroosmotic pumps with molecularly thin nanomembranes — University of Rochester, 2016, US
- Electro-osmotic pumps — Board of Regents of the University of Texas System, 2015, EP
- Electro-osmotic pumps with electrodes comprising a lanthanide oxide or an actinide oxide — Board of Regents of the University of Texas System, 2014, US
- Electro-osmotic pumps, systems, methods, and compositions — NAGARALE, RAJARAM (University of Texas system), 2013, US
- Electroosmotic pump and fluid pumping system having same — Sogang University Research Foundation, 2016, EP
- Electroosmotic devices — Old Dominion University Research Foundation, 2012, US
- Improvements in and relating to electroosmotic pumps — General Electric Company, 2014, EP
- Electroosmotic microchannel cooling system — Stanford University, 2004, US
- Electroosmotic flow pump system and electroosmotic flow pump — Nano Fusion Technologies, Inc., 2007, EP
- NIST — National Institute of Standards and Technology (electric double layer reference)
- WHO — World Health Organization (implantable drug delivery and kidney disease context)
- NIH / PubMed — National Institutes of Health (nanomembrane EO pump research funding)
- IEEE — Institute of Electrical and Electronics Engineers (microfluidic thermal management)
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This landscape is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.